Maria Carla Bosco

List of Publications by Year
in descending order

69 papers	2,973 citations	159358 30 h-index	168136 53 g-index
72 all docs	72 docs citations	72 times ranked	4555 citing authors

#	Article	IF	Citations
1	miR-23a contributes to T cellular redox metabolism in juvenile idiopathic oligoarthritis. Rheumatology, 2022, 61, 2694-2703.	0.9	4
2	Exosomal MicroRNAs as Potential Biomarkers of Hepatic Injury and Kidney Disease in Glycogen Storage Disease Type Ia Patients. International Journal of Molecular Sciences, 2022, 23, 328.	1.8	5
3	Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma. Cancers, 2021, 13, 2809.	1.7	10
4	The SGLT2-inhibitor dapagliflozin improves neutropenia and neutrophil dysfunction in a mouse model of the inherited metabolic disorder GSDIb. Molecular Genetics and Metabolism Reports, 2021, 29, 100813.	0.4	4
5	Transcriptome analysis defines myocardium gene signatures in children with ToF and ASD and reveals disease-specific molecular reprogramming in response to surgery with cardiopulmonary bypass. Journal of Translational Medicine, 2020, 18, 21.	1.8	11
6	Hypoxia Predicts Poor Prognosis in Neuroblastoma Patients and Associates with Biological Mechanisms Involved in Telomerase Activation and Tumor Microenvironment Reprogramming. Cancers, 2020, 12, 2343.	1.7	36
7	Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1). Cancers, 2020, 12, 1337.	1.7	14
8	Circulating exosomal microRNA as potential biomarkers of hepatic injury and inflammation inGlycogen storage disease type 1a. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	8
9	Targeting hypoxia in tumor: a new promising therapeutic strategy. Journal of Experimental and Clinical Cancer Research, 2020, 39, 8.	3.5	38
10	Macrophage polarization: Reaching across the aisle?. Journal of Allergy and Clinical Immunology, 2019, 143, 1348-1350.	1.5	42
11	Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study. Cancers, 2019, 11, 1476.	1.7	43
12	A Proteomic Analysis of GSD-1a in Mouse Livers: Evidence for Metabolic Reprogramming, Inflammation, and Macrophage Polarization. Journal of Proteome Research, 2019, 18, 2965-2978.	1.8	8
13	Characterization of high- and low-risk hepatocellular adenomas by magnetic resonance in an animal model of glycogen storage disease type 1A. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	4
14	PIPE-T: a new Galaxy tool for the analysis of RT-qPCR expression data. Scientific Reports, 2019, 9, 17550.	1.6	12
15	Dr. Luigi (Gigi) Varesio: A memorial. Journal of Leukocyte Biology, 2018, 103, 1251-1251.	1.5	0
16	Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration. Frontiers in Immunology, 2018, 9, 2358.	2.2	104
17	Development and characterization of an inducible mouse model for glycogen storage disease type Ib. Journal of Inherited Metabolic Disease, 2018, 41, 1015-1025.	1.7	6
18	Mesenchymal Stem Cell-Derived Extracellular Vesicles as Mediators of Anti-Inflammatory Effects: Endorsement of Macrophage Polarization. Stem Cells Translational Medicine, 2017, 6, 1018-1028.	1.6	399

#	Article	IF	Citations
19	Regulation of Human Macrophage M1â€“M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1. Frontiers in Immunology, 2017, 8, 1097.	2.2	208
20	Immunohistochemical analysis of PDK1, PHD3 and HIF-1Î± expression defines the hypoxic status of neuroblastoma tumors. PLoS ONE, 2017, 12, e0187206.	1.1	10
21	Mechanisms of Cancer-related Cardiomyopathy67Protection against chemotherapy cardiotoxicity by the human amniotic fluid stem cell secretome: a new tool for future paracrine therapy68Hyperlipidaemia reduces mortality in breast, prostate, lung and bowel cancer69DNA-repair in cardiomyocytes is critical for maintaining cardiac function. Cardiovascular Research, 2016, 111, S14-S15.	1.8	1
22	Artificial neural network classifier predicts neuroblastoma patientsâ€™ outcome. BMC Bioinformatics, 2016, 17, 347.	1.2	32
23	Regulation of Langerhans cell functions in a hypoxic environment. Journal of Molecular Medicine, 2016, 94, 943-955.	1.7	10
24	Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma. JAMA Ophthalmology, 2016, 134, 1125.	1.4	7
25	The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity. Scientific Reports, 2016, 6, 29994.	1.6	52
26	Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer. Current Pharmaceutical Design, 2016, 22, 6209-6233.	0.9	36
27	Dbl oncogene expression in MCF-10 A epithelial cells disrupts mammary acinar architecture, induces EMT and angiogenic factor secretion. Cell Cycle, 2015, 14, 1426-1437.	1.3	2
28	Identification of CD300a as a new hypoxia-inducible gene and a regulator of CCL20 and VEGF production by human monocytes and macrophages. Innate Immunity, 2014, 20, 721-734.	1.1	23
29	Development of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-Î± deficiency. DMM Disease Models and Mechanisms, 2014, 7, 1083-1091.	1.2	20
30	Identification of a novel mouse Dbl proto-oncogene splice variant: Evidence that SEC14 domain is involved in GEF activity regulation. Gene, 2014, 537, 220-229.	1.0	6
31	Hypoxia and Gene Expression. Cancer Drug Discovery and Development, 2014, , 91-119.	0.2	2
32	Hypoxia downregulates the expression of activating receptors involved in <scp>NK</scp>â€cellâ€mediated target cell killing without affecting <scp>ADCC</scp>. European Journal of Immunology, 2013, 43, 2756-2764.	1.6	210
33	Chronic hypoxia reprograms human immature dendritic cells by inducing a proinflammatory phenotype and <scp>TREM</scp>â€1 expression. European Journal of Immunology, 2013, 43, 949-966.	1.6	49
34	The hypoxic environment reprograms the cytokine/chemokine expression profile of human mature dendritic cells. Immunobiology, 2013, 218, 76-89.	0.8	59
35	Dendritic cell reprogramming by the hypoxic environment. Immunobiology, 2012, 217, 1241-1249.	0.8	32
36	Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome. BMC Bioinformatics, 2012, 13, S13.	1.2	15

#	Article	IF	Citations
37	Treatment of newborn G6pc mice with bone marrow-derived myelomonocytes induces liver repair. Journal of Hepatology, 2011, 55, 1263-1271.	1.8	8
38	Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. Blood, 2011, 117, 2625-2639.	0.6	119
39	The Tumor Suppressor Hamartin Enhances Dbl Protein Transforming Activity through Interaction with Ezrin. Journal of Biological Chemistry, 2011, 286, 29973-29983.	1.6	10
40	Macrophage-inflammatory protein-3Î±/CCL-20 is transcriptionally induced by the iron chelator desferrioxamine in human mononuclear phagocytes through nuclear factor (NF)-ÎºB. Molecular Immunology, 2010, 47, 685-693.	1.0	16
41	Abstract 2002: Cell reprogramming by hypoxia. , 2010, , .		0
42	The Hypoxic Synovial Environment Regulates Expression of Vascular Endothelial Growth Factor and Osteopontin in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 1318-1329.	1.0	31
43	Hypoxic synovial environment and expression of macrophage inflammatory protein 3Î³/CCL20 in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 58, 1833-1838.	6.7	35
44	Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration. Immunobiology, 2008, 213, 733-749.	0.8	138
45	Hypoxia transcriptionally induces macrophage-inflammatory protein-3Î±/CCL-20 in primary human mononuclear phagocytes through nuclear factor (NF)-ÎºB. Journal of Leukocyte Biology, 2008, 83, 648-662.	1.5	46
46	Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1Î± and -2Î±. Molecular Cancer Therapeutics, 2008, 7, 1974-1984.	1.9	73
47	Hypoxia inhibits Moloney murine leukemia virus expression in activated macrophages. Journal of Leukocyte Biology, 2007, 81, 528-538.	1.5	10
48	Hypoxia Modifies the Transcriptome of Primary Human Monocytes: Modulation of Novel Immune-Related Genes and Identification Of CC-Chemokine Ligand 20 as a New Hypoxia-Inducible Gene. Journal of Immunology, 2006, 177, 1941-1955.	0.4	189
49	Induction of Apoptosis by Flavopiridol in Human Neuroblastoma Cells Is Enhanced under Hypoxia and Associated With N-myc Proto-oncogene Down-Regulation. Clinical Cancer Research, 2004, 10, 8704-8719.	3.2	17
50	Hypoxia Selectively Inhibits Monocyte Chemoattractant Protein-1 Production by Macrophages. Journal of Immunology, 2004, 172, 1681-1690.	0.4	84
51	Picolinic acid- or desferrioxamine-inducible autocrine activation of macrophages engineered to produce IFNÎ³: an approach for gene therapy. Gene Therapy, 2004, 11, 560-568.	2.3	8
52	Hypoxia inhibits the expression of the CCR5 chemokine receptor in macrophages. Cellular Immunology, 2004, 228, 1-7.	1.4	57
53	Macrophage Activating Properties of The Tryptophan Catabolite Picolinic Acid. Advances in Experimental Medicine and Biology, 2003, 527, 55-65.	0.8	33
54	Antagonistic effect of picolinic acid and interferon-Î³ on macrophage inflammatory protein-1Î±/Î² production. Cellular Immunology, 2002, 220, 70-80.	1.4	14

#	Article	IF	Citations
55	Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. International Journal of Cancer, 2002, 99, 658-664.	2.3	45
56	Generation of high-titer retroviral vector-producing macrophages as vehicles for in vivo gene transfer. Gene Therapy, 2001, 8, 431-441.	2.3	19
57	Engineering of Macrophages to Produce IFN-Î³ in Response to Hypoxia. Journal of Immunology, 2001, 166, 5374-5380.	0.4	49
58	The Tryptophan Catabolite Picolinic Acid Selectively Induces the Chemokines Macrophage Inflammatory Protein-1Î± and -1Î² in Macrophages. Journal of Immunology, 2000, 164, 3283-3291.	0.4	108
59	IL-2 Signaling in Human Monocytes Involves the Phosphorylation and Activation of p59<i>hck</i>1. Journal of Immunology, 2000, 164, 4575-4585.	0.4	21
60	The Antineoplastic Agent Bryostatin-1 Induces Proinflammatory Cytokine Production in Human Monocytes: Synergy With Interleukin-2 and Modulation of Interleukin-2RÎ³ Chain Expression. Blood, 1997, 89, 3402-3411.	0.6	34
61	Multiple Cytokines Inhibit Interleukin-6-Dependent Murine Hybridoma/Plasmacytoma Proliferation. Cellular Immunology, 1996, 168, 117-121.	1.4	14
62	Interleukin-2 and human monocyte activation. Journal of Leukocyte Biology, 1995, 57, 13-19.	1.5	76
63	LPS-inducible nuclear factor in human monocytes that binds the negative regulatory element of the HIV LTR. Journal of Leukocyte Biology, 1994, 56, 21-26.	1.5	6
64	Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.. Journal of Clinical Investigation, 1994, 94, 2317-2325.	3.9	52
65	Inhibition of tumor growth and enhancement of metastasis after transfection of the Î³-interferon gene. International Journal of Cancer, 1993, 55, 320-329.	2.3	89
66	Ultrastructural evidence of the mechanisms responsible for interleukinâ€4â€activated rejection of a spontaneous murine adenocarcinoma. International Journal of Cancer, 1993, 53, 988-993.	2.3	33
67	The necessity of animal experimentation in tumor immunology. , 1990, , 125-132.		0
68	Lymphokine-activated tumor inhibition: Combinatory activity of a synthetic nonapeptide from interleukin-1, interleukin-2, interleukin-4, and interferon-Î³ injected around tumor-draining lymph nodes. International Journal of Cancer, 1989, 44, 62-65.	2.3	10
69	The effects of a long term dihydroergotoxine treatment on agonist and antagonist striatal dopamine binding sites are dose and age related. Pharmacological Research Communications, 1986, 18, 967-978.	0.2	3